+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Three-year follow-up of the use of a levonorgestrel-releasing intrauterine system in hormone replacement therapy



Three-year follow-up of the use of a levonorgestrel-releasing intrauterine system in hormone replacement therapy



Acta Obstetricia et Gynecologica Scandinavica 76(2): 145-150



Background. The efficacy of a levonorgestrel-releasing intrauterine system in opposing endometrial proliferation and in preventing bleeding was studied in peri- and postmenopausal women receiving estrogen replacement therapy. Methods. This was an open, non-controlled follow-up study of the use of a levonorgestrel-releasing intrauterine system during continuous estrogen replacement therapy carried out by using oral, transdermal or subdermal estradiol. The efficacy of the progestin therapy was evaluated by transvaginal ultrasonography and by examination of endometrial biopsy samples taken 20 months (mean, range 17-22; first evaluation) and 34 months (mean, range 31-38 months; second evaluation) after insertion of the levonorgestrel-releasing intrauterine system, and by studying patterns of bleeding. Twenty-five women participated in the first evaluation, and 29 in the second. Results. Seventy-six percent of the women were amenorrheic at the first evaluation, and 79% at the second evaluation. Others had spotting for 1-2 days monthly or less often. The mean time until amenorrhea was reached was 6 months (range 2-13 months) after insertion of the levonorgestrel-releasing intrauterine system. The median endometrial thickness assessed by ultrasound was 2 mm at both evaluations. No signs of proliferation were observed in any of the endometrial samples. Conclusions. Local progestin delivery via a levonorgestrel-releasing intrauterine system was effective in suppressing the endometrium and in eliminating bleeding in women receiving estrogen replacement therapy, and the intrauterine progestin therapy was also well accepted.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 009646214

Download citation: RISBibTeXText

PMID: 9049288

DOI: 10.3109/00016349709050071


Related references

A 5-year follow-up study on the use of a levonorgestrel intrauterine system in women receiving hormone replacement therapy. Fertility & Sterility 76(5): 969-973, 2001

The levonorgestrel intrauterine system in menopausal hormone replacement therapy: Five-year experience. Fertility & Sterility 72(1): 161-163, 1999

Effect of the levonorgestrel-releasing intrauterine system on the uterine artery pulsatility index in postmenopausal hormone replacement therapy. Ultrasound in Obstetrics and Gynecology 10(5): 350-355, 1998

Effects of hormone therapy on the endometrium in postmenopausal women: a one year randomized trial of low dose oral estradiol in association with a levonorgestrel-releasing intrauterine system or drospirenone. Revista Brasileira de Saúde Materno Infantil 13(3): 259-266, 2013

Percutaneous estradiol gel with an intrauterine levonorgestrel releasing device or natural progesterone in hormone replacement therapy. Maturitas. 26(3): 211-217, 1997

Sustained-release estradiol implants and a levonorgestrel-releasing intrauterine device in hormone replacement therapy. American Journal of Obstetrics & Gynecology 172(2 PART 1): 562-567, 1995

Predictors of oligoamenorrhea at 1-year follow-up in premenopausal women using a levonorgestrel-releasing intrauterine system. Contraception 76(2): 91-95, 2007

A 3-year follow-up of women with endometriosis and pelvic pain users of the levonorgestrel-releasing intrauterine system. European Journal of Obstetrics, Gynecology, and Reproductive Biology 143(2): 128-129, 2009

Effects of levonorgestrel-releasing intrauterine system on glucose and lipid metabolism: a 1-year follow-up study. Contraception 73(5): 528-531, 2006

Endometrial morphology during hormone replacement therapy with estradiol gel combined to levonorgestrel-releasing intrauterine device or natural progesterone. Acta Obstetricia Et Gynecologica Scandinavica. 77(7): 758-763,., 1998

Acceptability of the long-term contraceptive levonorgestrel-releasing intrauterine system (Mirena): a 3-year follow-up study. Contraception 67(2): 87-91, 2003

Levonorgestrel-releasing intrauterine system (LNG-IUS) as an effective treatment option for endometrial hyperplasia: a 15-year follow-up study. Fertility and Sterility 95(1): 420-422, 2011

The levonorgestrel-releasing intrauterine system in human immunodeficiency virus-infected women: a 5-year follow-up study. American Journal of Obstetrics and Gynecology 204(2): 126.E1-4, 2011

The levonorgestrel-releasing intrauterine system for endometrial protection during estrogen replacement therapy: a clinical review. Climacteric 18(4): 470-482, 2016

Clinical outcomes and costs with the levonorgestrel-releasing intrauterine system or hysterectomy for treatment of menorrhagia: randomized trial 5-year follow-up. JAMA 291(12): 1456-1463, 2004